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Transplant glomerulopathy (TG) is a major cause of chronic graft dysfunction without effective therapy. Although the histological
definition of TG is well characterized, the pathophysiological pathways leading to TG development are still poorly understood.
Electron microscopy suggests an earlier appearance of TG and suggests that endothelial cell injury is the first sign of the disease.
The pathogenic role of human leukocyte antigen (HLA) antibodies in endothelial cells has been described in acute vascular and
humoral rejection. However themechanisms and pathways of endothelial cell injury byHLA antibodies remain unclear. Despite the
description of different causes of the morphological lesion of TG (hepatitis, thrombotic microangiopathy), the strong link between
TG and chronic antibody mediated rejection suggests a major role for HLA antibodies in TG formation. In this review, we describe
the effect of classes I or II HLA-antibodies in TG and especially the implication of donor specific antibodies (DSA). We update
recent studies about endothelial cells and try to explain the different signals and intracellular pathways involved in the progression
of TG.
1. Introduction
Since the 1970s, kidney transplantation has served as the
strong hold to cure chronic kidney disease. However more
than 50% of transplant recipients experience late allograft
rejection after 5 to 10 years which presents as a significant
clinical problem and remains a major barrier to maximiz-
ing the utility of transplanted kidneys. Recurrent primary
disease, toxicity of immunosuppressive therapy, and late
renal rejection all contribute to late transplant loss and
significantly reduce the transplant half-life. Whilst acute
antibody mediated rejection (AMR) is well recognised as an
early cause of graft dysfunction, the chronic late lesion of
AMR is less well studied and therapeutic strategies to treat
this entity are lacking.With the improvement inmanagement
of acute rejection and acute rejection rates now being less
than 15% in many centres, management of chronic antibody
mediated rejection and its final pathological entity transplant
glomerulopathy (TG) has become a major unmet need of
transplant nephrology, for which new treatment strategies are
urgently required. Prior to 2005 the term “chronic allograft
nephropathy” was used to cover a variety of pathological
lesions without specific cause. Transplant glomerulopathy
itself is a form of chronic allograft nephropathy with poor
graft outcomes and a distinctive pathological appearance
[1–5]. However, a recent study showed different outcomes
between these 2 entities [6].
The pathological features of TG include a multilami-
nation and double contour formation of glomerular base-
ment membrane (GBM) in the absence of immune-complex
deposit and are identifiable by Periodic Acid Schiff or silver
staining using light microscopy.
Patients with a TG histological diagnosis present fre-
quently with a nephrotic range proteinuria and/or hyper-
tension and/or kidney graft function deterioration as illus-
trated in Table 1. Peritubular capillary C4d staining has
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also been considered recently for the diagnosis of antibody
mediated kidney rejection but is not correlated well with
TG. Interestingly, study using electron microscopy showed
early modification of endothelial cells (EC) suggesting earlier
appearance of TG [6–10].
The new concept EC injury predefining TG raises the
question about the possible crosstalk between these cells
and HLA antibodies [11]. Despite different medical strategies
(based on acute humoral rejection treatment strategies) to
treat TG, none of them appear effective [12]. Some trials with
new drugs like eculizumab or bortezomib are ongoing and
suggest a noncomplement pathway in TG [13].
This review will cover the morphology and clinical
outcomes of TG, the role of HLA antibodies, and a focus on
EC injury as a key concept in the TG process.
2. Definition of Transplant
Glomerulopathy (TG)
TG was first recognised in the early 1980s with characteristic
features defined as mesangial and EC changes in trans-
plantation kidney graft biopsies [14]. The cardinal features
observed in biopsy series included (i) light microscopy
identifying a duplication of glomerular basement membrane
(GBM), mesangial matrix expansion, and glomerulitis, (ii)
electron microscopy (EM) identifying a loss of endothelial
fenestration, endothelial cell swelling, and mesangial matrix
expansion, and (iii) immunofluorescence identifying mesan-
gial IgM and C3 staining ± C4d in glomerular cells and
peritubular capillaries [15, 16]. The manifestations of all these
changes are only observed in the lesions of advanced TG
but are frequently absent in the early TG lesion. Basement
membrane lamellation, which is the earliest sign of TG can be
detected by EMwithin the first 3 months posttransplantation
[8] which supports use of early protocol biopsies to survey
the allograft to predict its decline in function [17]. Figure 1
summarizes histological lesions observed in TG. Being asso-
ciate with these light and electronic microscopic lesions, our
group frequently observed the presence of PCT inflammation
which raises the question about the earliest target in TG. It
is tantalising to predict that EC are the first target of HLA
class I Ab as they are present in the surface of glomerular and
juxtaposed to the PCT cells. Is it possible that lymphocytes
use the same process to aggress the glomerular and/or PCT
ECs via a possible link with HLA Ab and thereby increases
the risk of TG development?
Despite TG being recognised for more than 30 years ago,
the mechanisms involved in the development of TG remain
largely unknown. Other histological appearances in graft
recipients (e.g., thrombopathic microangiopathy, membra-
noproliferative glomerulonephritis, or lupus nephritis) make
the diagnosis difficult [18].
3. TG Risk Factors and Clinical Outcome
The development of TG is associated with poor kidney graft
outcomes [1–5]. A number of associated factors for the
development of TG have been identified of the recipients
including age, presence of antibodies directed towards HLA
molecules especially class II donor specific antibodies (DSA),
C hepatitis positive serology (HCV), and last acute rejection
beyond 3 months post-Tx [9, 19]. Unfortunately de novo
DSA appearance has been identified in younger recipients
and attributed to their noncompliance to immunosuppressive
therapy [20]. De novo DSA after transplant result in the
increase of chronic humoral injury with development of TG
[21].
Gloor et al. showed also that subclinical TG detected in
protocol biopsies affects long-term graft outcomes [19]. Our
previous study showed that allografts presenting with TG
10 years after transplantation experienced a 33% reduction
in graft survival versus 63% in the matched control group
[22]. This has been confirmed in other reports [4, 10]. It
has been observed that around 4% and 20% of transplant
patients present with TG at 1 and 5 years, respectively,
after transplantation [19] but some studies showed a lower
cumulative incidence of TG [9, 10, 16, 23]. In a previous
16-year retrospective registry analysis we observed a TG
diagnosis in 4% of patients [22]. The true frequency of
TG is probably underestimated because many centers do
not perform protocol systematic biopsy and likely miss the
subclinical TG [24]. The mean duration from transplant to
diagnosis of TG is 2 to 9 years in clinically indicated biopsies
[9, 19, 22, 25, 26]. The main presentation of the earlier
stage of clinical TG is the late appearance of subnephrotic
range proteinuria [9, 10]. In some cases it is associated with
hypertension and ultimately with decline renal function as a
late and inevitable complication. A recent study confirms that
the appearance of proteinuria one year after transplantation
without evidence of TG may predict the development of TG
5 years after transplantation in sensitized patients [4].
4. HLA Antibody and Association with TG
It is well accepted that HLA DSA are associated with poor
kidney allograft outcomes and that their presence is strongly
associated with the development of TG. Preformed DSA,
which are present at the time of transplant, persisting after
transplantation despite desensitization therapy or de novo
DSA are considered a risk factor contributing to TG [27, 28].
We previously showed that 50% of patients presenting
with TG had DSA and poor graft survival [22]. Moreover
it is well documented that TG is associated with humoral
rejection according to the Banff criteria [29, 30]. The pres-
ence of HLA antibodies and/or the presence of peritubular
capillary inflammation were/was often associated with GBM
thickening [30]. The term of chronic allograft nephropathy
disappeared after the 2005 Banff meeting [31]; TG term still
remains applicable with an overlapping between TG and
chronic humoral rejection [26] in part mediated by DSA.
More recently a French study confirmed the association
of TG anti-HLA antibodies and a new defined antibody-
mediated vascular rejection in kidney allograft [32]. The
second part of chronic humoral rejection diagnosis is based
on peritubular capillary (PTC) C4d deposits [29] similar to
the acute humoral rejection criteria [31].




Figure 1: Histopathology of transplant glomerulopathy. (a) Light microscopy showing TGwith a glomeruli showing sclerosis (periodic-acid-
Schiff stain ×400). (b) Light microscopy showing glomerulitis (presence of mononuclear cells in glomerular capillaries) in a biopsy specimen
(periodic-acid-Schiff stain ×600) (c) Silver staining highlighting double contouring of the glomerular capillary wall (×400). (d) Electron
microscopy showing duplication of the glomerular basement membrane—arrows (×8000) (e) Peritubular capillitis (arrow) in a TG biopsy
specimen (periodic-acid-Schiff ×600) (f) Peritubular C4d staining in a TG biopsy (immunofluorescence ×400).
5. C4d Staining in Transplant Glomerulopathy
The demonstration of antibody deposition in the graft is an
important component of making a diagnosis of antibody
mediated allograft injury. The last Banff working group
meeting revised in 2011 the definition of antibody medi-
ated rejection (AMR) and acknowledged that the chronic
humoral rejection and/or TG development could be C4d
negative [7, 33]. PCT C4d staining biopsies is strongly
associated with DSA in TG biopsies [19, 26]. Glomerular
C4d may occur without C4d staining in PTC in recipi-
ents who frequently presented with DSA [9, 19, 34, 35].
Glomerular C4d deposition is a useful additional marker
for making the diagnosis of TG and has been proposed as
an index of severity in TG. Indeed Batal et al. observed
significant higher chronic glomerular lesion score (cg) in
paraffin-embedded biopsies that were associated with pos-
itive glomerular basement membrane staining as well as a
trend toward a significant difference in frozen specimenswith
glomerular staining [36]. The interpretation of glomerular
C4d staining is further complicated by the choice of tissue
in which it is detected. Normal glomeruli examined by
immunofluorescence in frozen section may show periph-
eral C4d staining and therefore use of paraffin section is
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preferred when seeking evidence of glomerular deposition
[37]. Loupy et al. described different stages of TG mediated
by preformed DSA according to early kidney graft biopsies
[27]. The remaining question about the DSA threshold and
subsequent development of TG is still unclear and needs to
be addressed with further studies including patients with
DSA after transplantation [38]. Despite its usefulness when
present, C4d staining can be problematic in that its detection
varies depending on biopsy series and technique employed
for detection [37]. Chronic antibody mediated injury likely
occurs in wave like patterns, with variable antibody pro-
duction, and therefore biopsy may potentially miss periods
of peak antibody production and therefore C4d positivity.
These pathogenic variations in disease activity and variation
in technical detection techniques therefore largely account
for the range of C4d positivity reported in biopsy series,
which ranges between 25–61% of TG cases described in the
literature. Avoiding overdependence on C4d as a diagnostic
cornerstone of antibody-mediated rejection and taking other
factors into consideration, for example, presence of DSA and
other histological evidence of TG (glomerulitis/PTCitis), are
likely to contribute to better diagnosis in the future, but
this will require further studies to confirm the utility of
these factors. Recently the concept of C4d negative antibody
mediated rejection has been proposed, which recognises that
C4d staining is problematic and proposes a new classification
which includes evidence of allograft injury based on light
microscopic features of glomerulitis (Banff “g” lesions) and
peritubular capillitis (“ptc” lesions). This new classification
from the Banff 2013 meeting has not yet been published and
validated but it may alter the diagnostic criteria for anti-
bodymediated rejection. Finally, newer techniques including
microarray analysis of TG biopsies may provide molecular
signals and intracellular pathway activation to allow the
diagnosis of TG without histological controversy and may
potentially identify new pathways that can be targeted in
intervention strategies.
6. HLA Antibody Specificity and TG
Table 1 summarized the percentage of class I and class II HLA
Abs in the different studies including TG patients. The link
between anti-HLADSA andTG iswell recognised.Moreover,
studies report the main risk factor of TG being DSA HLA
class II antibodies. However HLA class I antibodies have
also been identified [21]. A recent study demonstrated a
correlation between HLA class II Ab in de novo DSA after
transplantation and poor graft survival [20]. However com-
plete dominance of HLA class II Ab in TG is unlikely even
if some explanation has been proposed [20, 26, 39–41]. The
important question regarding the risk of TG according to the
time of DSA appearance needs to be addressed. For example,
are pretransplant DSA as deleterious as posttransplantation
DSA for TG lesion development? The majority of studies on
TG focused on DSA after transplantation [6, 9, 21] and in
fact excluded patients with DSA pretransplantation [19, 20].
We observed that pretransplant DSA were a risk factor of TG
but statistical analyses were not performed according to the
small number of TG patients. We also described a higher risk
of TG appearance in de novo DSA patient group [22]. Due
to the low number of recipients susceptible to develop TG,
the possibility to lead a prospective randomized controlled
trial is still unexpected. The high sensitized living kidney
transplantation should be a good model to analyse the risk
of DSA and TG.
The presence or absence of C4d staining deposition in
TG biopsies specimen correlates poorly with the presence of
HLA antibodies [26]. In a recent study, 31/48 AMR associated
with TG was C4d negative and the AMR was due to anti-
HLA class I and/or II in the same proportion [21]. Even if
TG occurred via either HLA class I antibodies or HLA class
II antibodies, 5-year graft survival in a large series of living
donor kidneys with positive cross match decreased widely
in class II sensitized patients as compared to that of class I
sensitized patients (85.3% versus 62.6%) [4]. The presence
of TG one year after transplantation results in graft loss in
30% of anti-HLA class II patients and approximately 20%
of those with anti-HLA class I antibodies [4]. These authors
also demonstrated a higher rate of chronic glomerulopathy
(defined by a cg score > 0), which is frequently associated
with chronic antibody mediated injury in the anti-HLA class
II patient group [4]. The reason explaining the greater effect
of anti-class II antibody as compared to class I antibody in
AMR and also in TG remains unknown.
Anti-DP antibodies have been reported in TG as an
only immunological cause in one patient presenting with
TG [42]. Anti-DQ DSA are increasingly recognized as the
predominantHLA class IIDSAproduced [43]. A recent study
showed the clinical relevance of anti-DQ antibodies in kidney
graft outcomes and confirms the pathogenic effect in cardiac
and liver transplantation [44, 45]. Patients with DQ-DSA are
at a higher TG risk. Interestingly, an association of Cw-DSA
in TG patients was not observed suggesting a major effect of
DQ DSA [46]. Issa et al. demonstrated a strong correlation
between anti-class II antibody titre and the risk of TG but did
not observe differences between anti-DR or anti-DQ subset
effects [47].
Notably, as half of the biopsies performed 5 years after
transplantation did not present evidence of TG, this raises the
question of the crucial crosslink of HLA antibodies and thus
suggests the involvement of other aetiologies’. To this end,
some studies did not confirm an association between HLA
antibodies and TG suggesting another possible mechanism
in TG formation [15]. Examples include patients positive for
HCVand those presentingwith thromboticmicroangiopathy
[18, 48].
7. Non-HLA Antibody Involvement in TG
Despite strong evidence for a correlation between HLA
antibodies and TG, the implication of non-HLA antibodies
has been suggested as a mechanism of glomerular damage
occurring after transplantation. The percentage of TG cases
in which HLA antibodies have not been identified is variable,
with one large series from Canada suggesting that up to 27%
of cases had no demonstrable antibody [26]. In our own
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series over 50% of cases of TG were associated with donor
specific HLA antibodies [22]. Some of TG cases presented
without anti-HLA antibodies or C4d staining [49] and recent
reports demonstrated the role of non-HLA antibody. This
autoreactivity has been well described in heart transplanta-
tion with antibody directed against myosin or vimentin [50].
Angiotensin II type 1 receptor (AT1R) antibody strongly cor-
relatedwithAMR in kidney transplantation independently of
DSA and confirming the rule of non-HLA Ab in acute graft
injury [51]. In our well-characterized cohort of TG patients
[22] we have recently identified AT1R antibodies in 52% of
cases with biopsy proven TG and importantly a group ofHLA
antibody negative TG cases in whom AT1R antibodies were
identified indicating for the first time that AT1R antibodies by
themselves are associated with TG (Hanf et al. submitted). In
pediatric cohort, recipients with antibodies to protein kinase
Czeta developed rejection and increased the risk of allograft
loss but TG was not described [52]. Using a protein screen-
ing microarray Dinavahi et al. showed that transplantation
induced changes in antibody repertoires reactive to non-
HLAAg and isolated three possible pretransplant serum anti-
bodies to peptidyl-propyl-isomerase-A, peroxisomal-trans-
2-enioyl-coA-reductase (PECR), and serine threonine kinase
6 correlating with TG development. Notably, only PECR
was confirmed by ELISA with a strong association between
it and TG [53]. Moreover a recent study using the same
process describes four new biomarkers predicting the future
development of chronic allograft injury in pretransplant
sampling: chemokine ligand 9 (MIG), interferon gamma
(IFN𝛾), chemokine ligand 11 (ITAC), and Glial-derived neu-
rotrophic factor [54]. Importantly, these recent pieces of data
were derived from a retrospective cohort and thus require
confirmation in large prospective studies.
8. Endothelial Cells and HLA Antibody:
Crosstalk to Develop TG?
Binding HLA antibodies to HLA molecules may cause
endothelial cell injury via the complement cascade and/or
may induce endothelial cell proliferation and survival via
intracellular signalling. Donor-specific anti-HLA alloanti-
bodies initiate renal allograft rejection through complement-
mediated and antibody-dependent cell-mediated cytotoxi-
city as previously described [55]. In a sensitized kidney
allograft cohort, 68% of tested sera were found to contain
complement-fixing alloreactivity. IgG1 type panel reactivity
was predominant (detectable for HLA class I and II reactiv-
ity), followed by IgG3, and both were independently corre-
lated. Complement fixation was also favored by the simulta-
neous presence of alloreactive IgG1, IgG3, and IgM [56]. IgG2
and IgG4 were more weakly involved in complement-fixing
activity [57].
Electron microscopy studies show that the endothelium
exhibits the first signs of injury, well before development
of TG [8]. The concept of endothelial injury is supported
by EC gene analysis showing a strong correlation of high
expression of endothelial cell-associated transcript (ENDAT)
and the presence of DSA correlating with late antibody
mediated rejection. In 2009, Sis et al. described that more
than 10 ENDAT genes increased ABMR predicting late graft
loss. Importantly, patients presenting with DSA without high
expression of ENDAT had better graft outcomes [57]. How-
ever, high ENDAT expression was also seen in borderline
TG changes, T cell rejection, or polyomavirus infection [58].
Thus this marker should be interpreted in association with
the presence of DSA to improve sensitivity [59]. These data
suggest the correlation between HLA antibodies and EC
injury mediated by complement dependent or independent
pathways in chronic ABMR.
Previous studies showed that binding antibodies to class
I molecules on the surface of endothelial cells results in
tyrosine phosphorylation of various intracellular proteins
(AKT, ERK. . .). The two major consequences of class I-
mediated phosphorylation are cell proliferation via upregu-
lation of fibroblast growth factor receptors (FGFR) on the
surface of endothelial cells and cell survival stimulation
by increased endothelial cells expression of antiapoptotic
proteins Bcl-2 and Bcl-xL via the P13K/Akt pathway [60,
61]. These observations raise an important question—what
are the factors that determine the outcomes of HLA class I
antibody-mediated phosphorylation?
As illustrated in Figure 2, studies by the Reed’s group
showed that stimulation of endothelial cell proliferation was
observed at concentrations of HLA antibodies ranging from
0.1–10 𝜇g/mL with maximal cell proliferation at concentra-
tions of 10 𝜇g/mL. On the other hand, treatment of endothe-
lial cells with HLA class I antibodies for 24 hours induced
a prominent increase in the prosurvival proteins Bcl-2 and
Bcl-xL protein levels; withmaximum increases observedwith
lower antibody concentrations antibodies were used (0.01–
1 𝜇g/mL) [61]. These findings suggest that concentration of
HLA antibodies is one of the factors contributing to the out-
comes of HLA class I antibodies-mediated phosphorylation
and gene expression. Furthermore, Iwasaki et al. showed that
low dose HLA class I antibody activates the AKT pathway
leading to the induction of antiapoptotic genes (Bcl-2) as
well as the cytoprotective genes HO-1 and ferritin H [62]
(Figure 2).
Recent in vitro work using human aortic EC addressed
the question of EC cytoskeleton and antibody mediated
rejection or transplant vasculopathy. In 2012 Zhang and Reed
demonstrated a mutual dependency between HLA I and
integrin subunit 𝛽4 to stimulate signal transduction and EC
proliferation [63]. Ziegler et al. improved the understand-
ing on HLA class I ligation EC pathway using both mass
spectrometry analysis on cytoskeleton structure [64] as well
as analysis on stress fiber formation [65]. As depicted in
Figure 3, results suggest a major contribution of ERK and
MLC phosphorylation in a calcium independent manner
and that the remodelling in EC structure may be involved
in chronic allograft rejection. Monocyte infiltration occurs
during graft injury and may also contribute to the risk of TG.
An elegant study by Valenzuela et al. showed, in vitro and in
vivo, a role for p-selectin in monocyte recruitment induced
by HLA class I Ab [66] (Figure 3). Taken together, these
results confirm the corner stone role of HLA antibodies in
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Figure 2: Intracellular signalling pathways mediated by high/low titre HLA class I antibodies after endothelial binding. Putative cell survival
and proliferation pathways are illustrated.
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Figure 3: Intracellular signalling pathways mediated by HLA class I or II antibody binding to endothelial cells.The observation that the main
HLA class I antibody binding stimulates intracellular EC pathways via the integrin 𝛽4 subunit is summarized in this figure. After stimulation
cytoskeleton remodelling and stress fiber formation via ERK pathway occur with calcium dependent and independent signalling leading to
possible TG development and inflammatory cell recruitment.
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the chronic rejection and thus warrant further investigation
in TG formation.
Interestingly, the majority of studies investigating anti-
body activity in EC injury were mediated by HLA class I
monoclonal antibodies leaving clear need to investigate class
II antibodies. One study investigated the effects of class I
and II antibodies on EC on cardiac allografts and showed
that phosphorylation of S6 ribosomal protein (S6RP), a
downstream target of the PI3K/Akt/mTOR pathway, was a
biomarker of antibody mediated rejection [67]. The authors
demonstrated that ligation of HLA class I and class II
molecules on EC resulted in increased phosphorylation of
S6RP. Then they showed in a cardiac biopsy that antibody
production to class II antigens was positively associated with
p-S6RP-positive staining and confirmed a strong association
between generation of DSA to class II antigens and EC
staining of p-S6RP staining. These observations were not
significant with class I Ab or DSA. These data suggest
crosstalk between class II Ab and EC but at present there
is a lack of in vitro or animal studies with class II DSA
or class II antibodies. Le Bas-Bernardet et al. showed that
DR expression was sufficient to trigger intracellular signaling
in EC isolated from human deceased donor, in response to
HLA-DR ligation. Crosslinking ofHLA-DR on ECs promotes
Akt activation and phosphorylation, suggesting that the PI3-
K pathway, involved in EC survival, was activated. These two
studies on class II antibodies raise the question of survival
signalling pathways contributing to EC changes. However
the EC used (from human large vessels) are quite different
from those of glomerular EC likely specifically involved in
the TG process [68, 69]. HLA antibodies tested in glomerular
EC subset demonstrated that these were able to produce
complement component (C3 and C4) [70].
Non-human primate studies in cynomolgus monkeys
have further added to our knowledge of the pathogenesis
of TG suggesting that there are 4 stages of the process.
The initiating stage is increased donor-specific antibodies,
followed by C4d deposition, then development of tissue
injury, and finally decrease in allograft function [71].
9. Treatment Options
Interestingly, the current recommendations in TG are not
based on randomized controlled trials or level 1 evidence
but rather on expert advice. Moreover, there is no efficient
treatment to limit TG progression with treatment based
on preventive recommendations (e.g., monitoring DSA,
avoiding and controlling antibody mediated rejection, and
reinforcing medication compliance) [72, 73]. The use of
antiproteinuric agents (e.g., ACE and ARB) is currently
ongoing [74]. Different desensitization protocols have been
used in sensitized patients at risk for antibody mediated
rejection [73, 74] and transplantation teams replayed these
different strategies in chronic ABMR and/or TG without
major significance benefits [12].
The diagnosis of TG in early stage should probably
be a goal but it requires systematic biopsies with electron
microscopy to dissect endothelial change. Thus it should
be recommended for electron microscopy to be performed
on all transplant biopsies in patients at risk of developing
TG to enable early detection of these changes. In line with
the recent consensus guideline on the testing and clinical
management issues associated with HLA and non-HLA
antibodies in transplantation protocol biopsies should be
performed once de novo DSA have been detected [38]. A
recent study showed a benefit in the rate of development of
TG in patients presenting glomerular ultrastructural changes
and DSA and receiving IG IV + plasmapheresis and/or
rituximab [15]. However a pilot study using rituximab did
not show efficacy in TG with stabilisation of TG in 50% of
the cases [48] but these results and other strategies should be
performed in prospective trials with TG andDSAmonitoring
as key end points in the trial design [38]. The use of ritux-
imab or splenectomy in incompatible ABO transplantation
was efficient to treat chronic ABMR in ABO incompatible
kidney transplantation with reduction of DSA titre [74].
Lefaucheur et al. suggested that using plasma exchange in
association with high dose of intravenous immunoglobulin’s
and rituximab reduced DSA level and AMR three years after
transplantation and thus reducing the risk of chronic AMR
[75].
Based on B cells depletion efficacy in experimental mod-
els [76, 77], bortezomib showed an efficacy in chronic AMR
case studies [78] and in AMR treatment [79]. A controlled
trial is ongoing to investigate if bortezomibwill prevent TG in
patients who are at high risk of developing the condition due
to high donor-specific alloantibody in posttransplant kidney
recipients (NCT01349595 on ClinicalTrials.gov).
The other new drug in the field is the C5 inhibitor
eculizumab (anti-C5 humanizedmonoclonal antibody; Alex-
ion, Cheshire, Connecticut). This agent was initially devel-
oped for paroxysmal nocturnal hemoglobinuria, the impli-
cation of complement pathway in AMR lead transplantation
team, to test eculizumab in sensitized patients with excellent
results [80]. It is also suggested that one of the pathways
resulting in TG is complement dependent due to the presence
of C4d deposition in biopsies. Stegall et al. showed that
sensitized patients receiving eculizumab decreased the rate
of AMR [81]. Even if the protocol biopsy at one year after
transplantation tends to show efficacy in TG development,
the same group present, during the American Transplanta-
tion Congress 2012, results until 2 years after transplantation
frompositive crossmatch patients receiving eculizumab.They
demonstrated similar rate of TG in both groups at two years
posttransplantation (50% versus 55% in eculizumab versus
control group, resp.) [82]. These results suggest that some
case of early TG may involve with independent complement
pathway.
10. Conclusion
TG remains a major cause of graft loss. We described a
strong correlation between EC injuries and HLA antibody
likely involved in TG process. The recent knowledge in
intracellular pathways involved in transplant vasculopathy
after HLA antibody ligation to their receptor in EC will
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likely improve in the future years and we hope that could be
extend to the concept of TG to develop new TG formation
blockade strategies. Treatment recommendations are mainly
preventive because treatment targeting HLA Ab or their
consequences did not shown encouraging results, especially
for eculizumab.Themain and only prospective study devoted
to TG is ongoing and should be an alternative to the current
therapy based on HLA Ab removal.
The unraised question about allo- or auto-non-HLA
antibody and TG remains open and warrants address to
determine the contribution of these antibodies in TG as well
as the HCV status and thrombotic microangiopathy disease.
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